Liontrust Investment Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Liontrust Investment Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-702,386	Closed	-$3.55M	–	202
2025 Q2	$3.55M	Buy	702,386 +107,331	+18%	+$527K	0.05%	136
2025 Q1	$3.15M	Sell	595,055 -336,672	-36%	-$2.45M	0.05%	137
2024 Q4	$6.3M	Sell	931,727 -58,273	-6%	-$392K	0.09%	115
2024 Q3	$7.42M	Hold	990,000	–	–	0.11%	107
2024 Q2	$7.42M	Buy	990,000 +240,000	+32%	+$2.09M	0.11%	107
2024 Q1	$7.48M	Buy	750,000 +235,000	+46%	+$2.62M	0.1%	110
2023 Q4	$5.08M	Sell	515,000 -5,000	-1%	-$35.7K	0.07%	120
2023 Q3	$3.98M	Buy	+520,000	New	+$5.19M	0.06%	122

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Liontrust Investment Partners's RXRX Position: Q3 2025 in Review

Liontrust Investment Partners sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 702,386 shares — an estimated $3.55M sold.

Liontrust Investment Partners first reported a position in RXRX in Q3 2023 and held it in 8 quarters. The position peaked at $7.48M in Q1 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

Liontrust Investment Partners reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Liontrust Investment Partners sold 702,386 Recursion Pharmaceuticals shares in Q3 2025, an estimated $3.55M.
Liontrust Investment Partners first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 8 quarters.
Liontrust Investment Partners's Recursion Pharmaceuticals position peaked at $7.48M in Q1 2024.
322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Liontrust Investment Partners's 13F filing for Q3 2025, filed 24 Nov 2025.